Company: SUPN
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001356576-25-000033
Chunk: 40

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 40
---
 We expect ASU 2024-03 to require additional disclosures in the notes to our consolidated financial statements. The Company is currently evaluating the effects adoption of this guidance will have on the consolidated financial statements.

9

3. Disaggregated Revenues 

The following table provides information regarding total revenues (dollars in thousands):Three Months EndedMarch 31,20252024(unaudited)Net product salesQelbree$64,745 $45,104 GOCOVRI30,689 26,562 APOKYN14,976 16,649 Trokendi XR12,801 15,989 Oxtellar XR10,198 26,943 Other(1)8,579 7,214 Total net product sales141,988 138,461 Royalty, licensing and other revenues7,836 5,183 Total revenues$149,824 $143,644 ___________________________________________(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.In December 2023, the Company submitted to the FDA a notification of discontinuance to withdraw Osmolex ER from distribution. Distribution of Osmolex ER ceased on April 1, 2024.

In the first quarter of 2025, the Company continued to have favorable actual returns experience for Qelbree. As such, the Company changed its estimated provision for product returns based on the most recent experience. Provision for product returns related to prior year sales for the three months period ended March 31, 2025 is less than 5% of net product sales; majority of this is attributable to Qelbree. Provision for product returns related to prior year sales for the three months period ended March 31, 2024 was less than 1% of net product sales. 

4. Investments 

Marketable SecuritiesUnrestricted available-for-sale marketable securities held by the Company are as follows (dollars in thousands):March 31, 2025December 31, 2024(unaudited)Corporate, U.S. government agency and municipal debt securitiesAmortized cost$347,903 $384,481 Gross unrealized gains12 89 Gross unrealized losses(173)(289)Total fair value$347,742 $384,281  As of March 31, 2025, all of our unrestricted available-for-sale marketable securities have contractual maturities